Frameworks for the Future: Implementing FDA Guidance on Artificial Intelligence in Biopharma
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Artificial Intelligence (AI) is transforming the pharmaceutical industry, from early drug discovery to post-market surveillance. The recent Food and Drug Administration (FDA) draft guidance “Artificial Intelligence in Drug and Biological Product Development”—outlines regulatory expectations for AI/ML in drug development, emphasizing transparency, reliability, and human oversight. This article compiles insights from regulatory discussions, technical literature, and real-world applications to examine how AI speeds up innovation while introducing new challenges. It highlights key opportunities in R&D, clinical development, manufacturing, and quality assurance, and discusses the future path for pharma and biotech organizations striving to responsibly incorporate AI into their operations.
Fields of Study & Subjects
Artificial Intelligence in Healthcare and Education
Computational Drug Discovery Methods
Artificial Intelligence Applications
Publication details
- Journal / source
- American Journal of Analytical Chemistry
- Volume
- 17
- Issue
- 03
- Pages
- 45–60
- Publication date
- 1 January 2026
- Language
- EN